Recovery from 3 Years of Daily Olfactory Distortions after Short-Term Treatment with GABA-Analogue.


Journal

ORL; journal for oto-rhino-laryngology and its related specialties
ISSN: 1423-0275
Titre abrégé: ORL J Otorhinolaryngol Relat Spec
Pays: Switzerland
ID NLM: 0334721

Informations de publication

Date de publication:
2023
Historique:
received: 14 03 2022
accepted: 15 07 2022
medline: 5 6 2023
pubmed: 6 9 2022
entrez: 5 9 2022
Statut: ppublish

Résumé

This case report describes a healthy 47-year-old man with a 3 years history of daily unpleasant olfactory distortions with severe negative effects on the quality of life. The distorted smoke-like smell occurred every day and was most prominent in the evenings resulting in severe discomfort as the patient felt suffocated by the smoke when falling asleep. The distorted smell had no odour triggers and was classified as phantosmia. Patient history, nasal endoscopy, neurological and otolaryngological examination, depression screening, cognitive testing, and CT scan revealed no obvious aetiology, resulting in the diagnosis of idiopathic phantosmia. Quantitate olfactory function was normal. Based on anecdotal evidence in the literature, the patient was treated with a GABA-analogue (pregabalin 50 mg × 3) for 4 weeks. During this treatment, the olfactory distortions completely disappeared for the first time in 3 years and had not reoccurred after 7 months of follow-up. GABA-analogues may be a potential treatment for some of the patients suffering from olfactory distortions. While this constitutes a single case report without controls and phantosmia can disappear spontaneously, there is no proof of causality. However, given the long duration of symptoms, temporal relationship with treatment on the sudden disappearance of phantosmia, and long follow-up without recurrence, this highlights the need for further studies on GABA-analogues as a potential treatment of idiopathic phantosmia. Consequently, larger studies and systematic evaluation of potential effects in different patient groups are warranted before routine treatment with GABA-analogues is advised.

Identifiants

pubmed: 36063798
pii: 000526211
doi: 10.1159/000526211
doi:

Substances chimiques

gamma-Aminobutyric Acid 56-12-2

Types de publication

Case Reports

Langues

eng

Sous-ensembles de citation

IM

Pagination

115-118

Informations de copyright

© 2022 S. Karger AG, Basel.

Auteurs

Alexander Wieck Fjaeldstad (AW)

Flavour Clinic, University Clinic for Flavour, Balance and Sleep, Department of Otorhinolaryngology, Regional Hospital Gødstrup, Herning, Denmark.
Flavour Institute, Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
Center for Eudaimonia and Human Flourishing, Linacre College, University of Oxford, Oxford, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH